Brian P. Calio

Brian P. Calio

Auto-generated profile, based on publicly available information

Brian P. Calio

National Cancer Institute, National Institutes of Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Urology
Verified
Journal Article
Closed access
ETEdouard J. Trabulsi
Edouard J. Trabulsi
BCBrian P. Calio
Brian P. Calio
SKSarah I. Kamel
Sarah I. Kamel
LGLeonard G. Gomella
Leonard G. Gomella
FFFlemming Forsberg
Flemming Forsberg
EHEthan J. Halpern
Ethan J. Halpern

1 January 2019 in Therapeutic Advances in Urology
Verified
Journal Article
Open access
PDF file
BCBrian P. Calio
Brian P. Calio
SDSandeep Deshmukh
Sandeep Deshmukh
DMDonald Mitchell
Donald Mitchell
CRChristopher G. Roth
Christopher G. Roth
ACAnne E. Calvaresi
Anne E. Calvaresi
CLCostas D. Lallas
Costas D. Lallas
The objective of this study was to determine if spatial distribution of multiparametric magnetic resonance imaging–transrectal ultrasound (mpMRI-TRUS) fusion biopsy cores to the index lesion reveals trends in the detection of intra-lesion Gleason heterogeneity and a more optimal prostate biopsy strategy. Index lesion was the lesion with longest diameter on T2-weighted (T2W)-MRI. In cohort 1, fusion biopsy cores biopsies were taken in areas in the center of the target as well as 1 cm laterally on each side. For cohort 2, targeted biopsies were taken from the center of the lesion only. Heterogeneity was defined as difference in maximum Gleason score obtained from fusion cores in the center of the index lesion versus cores obtained from the periphery (cohort 1), or any difference in maximum Gleason score obtained from fusion cores targeted to the index lesion (cohort 2) compared with systematic 12 cores TRUS biopsy. Ninety-nine consecutive patients (35 and 64 in cohorts 1 and 2, respectively) with median age (SD) and prostate-specific antigen (PSA) of 66.9 (±5.9) and 9.7 (±8.2) respectively, were included. Age, PSA, Prostate Imaging Reporting and Data System (PI-RADS) score, and preoperative MRI lesion size were not significantly different between cohorts. Gleason heterogeneity was observed at a significantly higher rate in cohort 1 versus cohort 2 (58% versus 24%; p = 0.041). In cohort 1, cores obtained from the center of the lesion had higher Gleason score than cores obtained from the periphery of the targeted lesion in 57% of cases. We demonstrate that there is observable tumor heterogeneity in biopsy specimens, and that increased number of cores, as well as cores focused on the center and periphery of the largest lesion in the prostate, provide more comprehensive diagnostic information about the patient’s clinical risk category than taking nonspecific cores targeted within the tumor.

5 December 2019 in International Urology and Nephrology
Verified
Journal Article
Open access
PDF file
DSDordaneh Sugano
Dordaneh Sugano
ASAbhinav Sidana
Abhinav Sidana
AJAmit L Jain
Amit L Jain
BCBrian Calio
Brian Calio
SGSonia Gaur
Sonia Gaur
PPPeter A. Pinto
Peter A. Pinto
Currently, there is a dearth of data concerning the impact of hypogonadism on prostate cancer detection by imaging. In this study, we evaluated the performance of multiparametric MRI (mpMRI) and mpMRI-TRUS fusion biopsy in hypogonadal patients.